Retinopathy of Prematurity clinical trials at UCSF

1 research study open to eligible people

Retinopathy of prematurity causes eye problems in premature infants. UCSF is exploring whether bevacizumab can help in severe cases. These clinical trials are looking for better ways to treat this eye disease.

Showing trials for

  • Bevacizumab Treatment For Type 1 ROP

    open to eligible people ages up to 6 months

    Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.

    San Francisco, California and other locations

Last updated: